Compare Heron Therapeutics Inc (HRTX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Under Armour Inc Class A trades at $7.3 (market cap $3.07B). The key difference: Under Armour Inc Class A is far larger — about 33.6× Heron Therapeutics Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | UAA | |
|---|---|---|
Market Cap | $91.46M | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $8.14 |
52-Week Low | $0.39 | $4.17 |
Enterprise Value | $189.36M | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Under Armour (UAA) trades at $7.28, down 2.02% amid mixed signals. The stock shows technical bullish momentum with strong moving average support, but faces fundamental challenges including a net loss of $201.27 million in 2025 and negative profit margins. Recent earnings showed Q4 2025 beat expectations but Q1 2026 missed, while the company maintains international growth momentum despite North American weakness.
The outlook remains cautious with analyst consensus price target of $5.96 below current levels. Investment opportunity exists in international expansion and DTC growth, but risks include persistent North American weakness, margin pressure, and negative cash flow trends that could pressure shareholder value in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
